Overexpression of p53 occurs in more than 50% of colorectal cancers. Therefore, p53 represents an attractive target antigen for immunotherapy. We assessed the safety of a canarypox virus encoding the human wild-type p53 gene given intravenously to endstage colorectal cancer patients in a three-step dose escalation study aimed at inducing p53 immune responses. Patients with metastatic disease of p53-overexpressing colorectal cancers were vaccinated three times at 3-week intervals, each time with 10 6.5 CCID 50 (CCID 50 ¼ cell culture infectious dose 50%; group 1, n ¼ 5), 10 7.0 CCID 50 (group 2, n ¼ 5) or 10 7.5 CCID 50 (group 3, n ¼ 6).
T umors are characterized by numerous changes in a variety of genes, resulting in altered products that can be unique targets for the immune system. Although the majority are expressed on both tumor cells and normal cells, the expression of these tumor-associated antigens (TAAs) has been found to differ significantly between normal cells and tumor cells, and thus may provide an immunotherapeutic window. Potential targets include carbohydrate antigens (e.g. gangliosides, blood groups antigens), viral antigens (e.g. HPV E6/E7), protein antigens (e.g. CEA, HER-2/neu, Ep-Cam) and mutated oncogene products (e.g. ras, p53, c-myc). 1 The p53 gene is a tumor suppressor gene located on the short arm of chromosome 17 that plays a pivotal role in ensuring genetic homeostasis. 2 Mutations in the p53 gene are the most common genetic alteration in many tumors and result in the production of a defective protein with a significantly longer than normal half-life of p53. 3 More than 50% of colorectal cancers demonstrate p53 overexpression, potentially allowing the tumor cells to be processed and the immunogenic epitopes to be presented to the immune system. 4 Although p53 is an auto-antigen, it has been demonstrated that humoral and cellular immune responses against p53 can be detected in cancer patients. [5] [6] [7] [8] [9] [10] Enhancing these responses could result in effective antitumor responses, but also induce a hazardous reaction to normal cells that have low expression levels of this auto-antigen.
Vaccination against p53 can be performed using genetically modified viral vectors allowing high expression of the transfected gene within antigen-presenting cells, thereby eliciting strong immune response against p53. The canarypox virus (ALVAC) is a well-characterized viral vector capable of infecting a variety of human cells. This vector, which cannot replicate in non-avian species, can nevertheless express inserted genes for up to a few days. This results in the induction of strong humoral and cellular responses against these gene products. 11 Hurpin et al. 12 compared subcutaneous, intramuscular, intradermal and intravenous (i.v.) administrations of ALVACp53 in mice and showed that only the i.v. vaccination route was capable of inducing CTL responses against p53. Subsequent studies showed that i.v. vaccination of mice with ALVAC-p53 resulted in long-term protection against challenges with p53 overexpressing tumors. Although, this does not resemble the clinical situation in which tumors are already present, Roth et al. 13 also showed that established p53-overexpressing tumors were successfully eradicated with i.v. ALVAC-p53 administrations.
The use of viral vectors in humans is associated with safety concerns for the patients and the environment, but as the canarypox virus is unable to replicate in mammalian cells, these concerns do not apply to ALVAC-based vaccines. Studies performed on rhesus macaques that received i.v. injections of the same lot of ALVAC-p53 used in the present study, with doses up to 10 times the proportional human dose, revealed no toxicity or auto-immune phenomena upon clinical or on histopathological evaluation. 14 The safety of ALVAC vector-based vaccines has been well established in various clinical trials where more than 1500 individuals, including cancer patients, have received ALVAC encoding a variety of genes such as the rabies glycoprotein gene, 15, 16 HIV envelope genes, 17, 18 CEA 19 and even multiple genes such as CEA and B7. 1. 20 In this study, we show that repeated i.v. administration of ALVAC-p53 in end-stage colorectal cancer patients is well tolerated and does not induce pathological auto-immunity, while stimulating p53-specific immune responses.
Methods

Patients
Patients older than 18 years with histologically proven colorectal cancer and evidence by imaging techniques of irresectable disease were eligible for inclusion. Patients with metastatic disease that was untreatable by conventional therapies and patients with metastatic disease that was potentially treatable, but who refused conventional therapy were also eligible. The study protocol was approved by the local and national medical ethics committees as well as by the biological safety committee and the Dutch Ministry of Health and Environment before the study started. The inclusion and exclusion criteria are summarized in Table 1 . Table 1 Inclusion and exclusion criteria for participation in the ALVAC-p53 study
Inclusion criteria
Histologically proven colorectal cancer Evidence of irresectable or metastatic disease in patients untreatable by conventional therapies, or in patients who are treatable by conventional therapies, but who refuse these Immunohistochemically proven expression of p53 and MHC class I in at least 30% of tumor cells Serum CEA X10 mg/l Age over 18 years Negative pregnancy test (for women of child-bearing age) Use effective contraception during the trial and up to 3 months after the last injection (for men and women) WHO performance status of 0-1 Renal function and bilirubin levels within 1.5 Â the normal upper and lower levels, ASAT and ALAT within 3 Â the normal upper value and alkaline phospahatase within 5x the normal upper value Signed informed consent Exclusion criteria Auto-immune disease Symptomatic viral or other infections HIV seropositivity or refusal to hear the result of the HIV test Organ grafts Life expectancy of less than 3 months History of allergy: severe asthma or atopic eczema or known allergy to egg products or neomycin History of severe neurological, cardiovascular, renal, hepatic, endocrine, respiratory or bone marrow dysfunction Known family history of Li-Fraumeni syndrome Chemotherapy (with the exception of nitrosurea), or radiation therapy within 4 weeks preceding inclusion Immunotherapy, chemotherapy using nitrosurea, or hormonal therapy (other than contraception) within 6 weeks preceding inclusion History of treatment with extracted growth hormone
Treatment and follow-up schedule
Patients were enrolled into three sequential groups of five individuals each and received three i.v. injections of ALVAC-p53 at 3-week intervals. At each of the three injections, patients in group 1 received a tenth (10 6.5 CCID 50 ) of the total dose of ALVAC-p53, patients in group 2 received a third (10 7 .0 CCID 50 ) of the total dose and patients in group 3 received the total dose (10 7.5 CCID 50 ). Patients were hospitalized for 24 hours after vaccination and vital signs (heart rate, blood pressure, rectal temperature and respiration rate) were measured just before and after vaccination, as well as 30 minutes, 1 hour, 6 hours and 24 hours after vaccination. Between hospital visits, patients documented symptoms and body temperature in a safety diary. A clinical history was taken and a physical examination was performed on each visit. Adverse events (clinical and biochemical) were scored according to the World Health Organization (WHO) recommendation for grading acute and subacute toxic effects. 21 Blood was obtained for biochemical (renal and liver function, C-Reactive Protein), hematological (hemoglobin level, hematocrit, leucocytes and differentiation, platelets), auto-immunity (anti-DNA antibodies and immune-complexes (ICX)) and CEA level assays, before each vaccination and during follow-up visits. Anti-DNA antibodies, 22 ICX levels 23 and immune responses against ALVAC and p53 were measured as previously described. 24 IgG antibody titers against ALVAC are presented as mean OD measured at 415 nm (dilution 1:800) minus the background. IgG antibody titers against p53 were considered positive when 41.1 U/ml. Patient visits were scheduled as follows: pre-inclusion visit (PV, a maximum of 2 weeks before V1); first vaccination (V1, week 0); second vaccination (V2, week 3); third vaccination (V3, week 6); V4 week 7; V5 week 8; V6 week 14 and V7 at week 20. All patients underwent a CT scan of the chest and abdomen a maximum of 2 weeks before the first vaccination (PV) and on the last follow-up visit, 14 weeks after the last vaccination (V7).
Recombinant ALVAC-p53 vaccine
The ALVAC-p53 (vCP207; Aventis Pasteur, Lyon, France) recombinant, expressing the human wild-type p53 gene, was constructed using the canarypox virusbased vector ALVAC. The vCP207 recombinant was generated by co-transfection of ALVAC-infected primary chick-embryo fibroblasts with an insertion plasmid and noninfectious purified ALVAC genomic DNA, leading to the integration of the foreign gene expression cassette into the viral genome via homologous recombination. The vaccine was purified twice through a sucrose gradient 12 and titrated based on the evaluation of the infectious titer of the preparation on a quail cell line, QT35 (continuous cell line derived from a chemically induced tumor in quail). The titer is expressed in CCID50/ml (number of cell culture infectious dose 50% per ml). Other quality assays performed include pH measurement, appearance, osmolality measurement, extractable volume, endotoxin content, bacterial and fungal sterility tests, abnormal toxicity tests, pyrogen assay identification, viral potency test and a particle count test.
Statistical analyses
The w 2 test, Kruskal-Wallis test (CEA) and the ANOVA (age and diagnosis metastases) tests were performed to analyze the differences between clinical and tumor characteristics between groups 1 to 3. A Po0.05 indicates a statistically significant difference.
Results
Patients
A total of 16 patients were enrolled in this dose-escalation study between April 1999 and December 2000 at the Department of Surgery of the Leiden University Medical Center. Characteristics of the study population are shown in Table 2 . There were 12 men and four women with a mean age of 60 years (range 42-71 years). Most patients (15/16) presented with metastatic disease, with the majority of patients suffering from liver (14/16 patients) and/or lung metastases (8/16 patients). Although, not statistically significant, the patients in the lowest dose group (group 1) were younger on average and seemed to have a higher tumor burden, as was reflected in the higher average CEA level at the start of the study and the higher frequency of treatment with second line chemotherapy and isolated liver perfusion. Only two out of five patients in group 1 were able to complete the planned 14 week follow-up after the last vaccination, whereas four out of five patients in group 2 and five out of six patients in group 3 completed the planned 14 week follow-up after the last vaccination. There were no statistically significant differences in patient-and tumor characteristics between the three groups (P-values not shown).
Alterations in the treatment and follow-up scheme
Patient 02 (group 1) developed a urosepsis 16 days after the first vaccination owing to progression of a local recurrence of a rectal carcinoma into the bladder wall. A urosepsis had previously occurred, 2 months prior to inclusion. Treatment and follow-up were postponed 2 weeks and radiation therapy was started to control the pain and rectal blood loss caused by the local recurrence. Patient 09 (group 2) requested chemotherapy after the third vaccination. The second line chemotherapy was started between V5 and V6 and resulted in WHO grade 4 diarrhea approximately 10 days later (45 days after the last ALVAC-p53 vaccination) which required hospitalization. During hospitalization, the patient developed an ileus and became critically ill. His condition improved without surgical intervention. Patient 13 (group 3) was discontinued from the study after the second vaccination because of disease progression (progression of recurrence of rectal carcinoma into the bladder wall) and was replaced to be able to analyze five patients having received all three vaccinations with the full dose. Patient 17 (group 3) requested chemotherapy after completing the vaccination schedule without significant problems. This was started after V6 (8 weeks after the last vaccination). Patient 08 (group 2) requested three additional vaccinations with the full dose as compassionate use after having received three vaccinations with 1/3 dose. This was performed outside the study protocol after receiving informed consent and approval from the appropriate committees.
Clinical safety
None of the patients experienced an anaphylactic reaction. A total of 382 clinical events (CE; 122 in group 1, 124 in group 2 and 136 in group 3) were observed during the study (V1-V7). This consisted of 16 serious adverse events (SAEs; 10 in group 1, three in group 2 and three in group 3) and 366 adverse events (AEs: 112 in group 1, 121 in group 2 and 133 in group 3). All SAEs were related to disease progression-related complications. The most frequent CE were: fever, alterations in liver biochemistry and tumor-related complications ((abdominal) pain, anemia and fatigue). The majority of clinical events (79%) was not related to administration of ALVAC-p53, but was a result of disease progression or intercurrent diseases. The other events were either possibly (11%), probably (5%) or definitely (5%) related to ALVAC-p53. Fever was the most common ALVAC-p53-related event (see Table 3 and Fig 1) . Grade 2 fever (38-401C) occurred significantly more often in group 3 patients and grade 3 fever (rectal temperature 4401C) was observed in group 3 only. There were no signs of concomitant hemodynamic or respiratory instability and the temperature normalized within 24 hours after vaccination, either spontaneously or after treatment with acetominophen (paracetamol). There were no clinical signs of treatment-related toxicity to the lungs.
Biochemical safety evaluation
Hurpin et al. 12 showed that after i.v. administration of ALVAC-p53 to mice, the virus was predominantly located in the lungs, liver and spleen. Therefore, toxic cytopathological effects caused by the virus were to be expected in these organs. Abnormalities in liver biochemistry (ASAT, ALAT, alkaline phosphatase and bilirubin) were frequent, but it should be noted that 14/16 patients had advanced liver metastases at the start of the study. Abnormal transaminase levels (ASAT440 U/l; ASA-T445 U/l) and alkaline phosphatase levels (4120 U/l) were already present before vaccination in 9/16 patients Safety of ALVAC-p53 in colorectal cancer AG Menon et al and 11/16 patients, respectively. There were no significant differences in transaminase levels, alkaline phophatase and bilirubin levels between the three groups. The electrolytes and renal function also showed no significant changes associated with vaccination. C-reactive protein levels also did not show changes consistent with an induction of a generalized immune response after vaccination.
Hematological evaluation
All five patients in group 1, 3/5 patients in group 2 and 4/ 6 patients in group 3 were anemic at baseline, as seen in many end-stage cancer patients. Hemoglobin levels declined during follow-up in nine patients, mainly in groups 1 (4/5 patients) and 2 (3/5 patients) and were related to disease progression. No differences in WHO anemia toxicity grades were apparent between the three groups (see Table 3 ). Leucopenia occurred mainly in group 2 and was attributable to second-line chemotherapy treatment of patient 09. The altered platelet levels in two patients of group 3 were already present at baseline and did not worsen after vaccination.
Immune responses and auto-immune safety
The patients in this study were significantly immunecompromised compared to healthy controls as they did not respond as well to control antigens such as M. tuberculosis, tetanus toxoid and C. albicans. 24 Antibody and cellular responses against ALVAC were detected in all but one patient. Antibody responses (IgG) against p53 were present before the vaccination in seven patients. In addition IgG (n ¼ 3) responses against p53 were induced in all three dose groups (Table 4) . Cellular responses against p53 were only induced in patients who had received the full dose. 24 Although anti-p53 immune responses were induced, no clinical signs of unwanted vaccine-induced auto-immune responses were detected. There was no serological evidence for an induction of a pathological auto-immune response, as illustrated by the results of the anti-DNA antibody-and immune complex assays. Anti-DNA antibodies were not present in any of the patients before and after vaccination. Immune complexes were not present or induced in 10 out of 16 patients. Two patients (02 and 07) had positive immune complexes before the first vaccination, and another four 
A dash indicates that no adverse events occurred for that particular adverse event.
Safety of ALVAC-p53 in colorectal cancer AG Menon et al patients had borderline levels of immune complexes after the vaccination scheme was completed. The formation of these immune complexes, however, was not related to ALVAC-p53. These data indicate that although responses against p53 were induced, this was not accompanied by the induction of a pathological auto-immune response. Of note, patient 08 received as part of compassionate treatment another vaccination treatment with the full dose of ALVAC-p53. Anti-ALVAC antibodies were induced after the first vaccination cycle and antibody levels were further enhanced after the second vaccination treatment. The mean OD (415 nm, dilution 1:800) increased from 0.04 before the first vaccination with 1/3 dose to a maximum of 0.92 two weeks after the third vaccination. Following the vaccination cycle with the full dose, anti-ALVAC antibodies were further boosted. The mean OD at 415 nm increased from 0.55 before the first vaccination with the full dose to a maximum of 2.4 one week after the third vaccination. An IgG response against p53 was present in this patient before participation and p53-specific antibody levels increased during both the first and second vaccination cycle with 1/3 and the full dose, respectively. The IgG level increased from 1.1 U/ml before receiving 1/3 dose to 3.9 U/ml after completing the vaccination cycle with the full dose. A cellular response was not detected after vaccinating with 1/3 dose and could not be tested after the full dose, because no material was available for these analyses. Tumor response CEA levels increased in 15/16 patients during the study. Patient 10 showed a relatively stable CEA level during the study. It was 196 mg/l before the first vaccination and 171 mg/l 14 weeks after the last vaccination. Disease progression, however, was outspoken clinically and radiographically.
Metastases were evaluated by CT scan 14 weeks after the last vaccination, except for patients 02, 09 and 17 for whom CT scans were performed 2, 4 and 8 weeks after the last vaccination, respectively. All patients showed progressive disease, including patient 08 after his first treatment cycle with 1/3 dose. After the second treatment cycle with the full dose, the follow-up CT scan, performed 7 weeks after the last vaccination, revealed stable disease (see Fig 2) .
Discussion
In this study we administered a recombinant canarypox virus encoding the human wild-type p53 gene (ALVACp53) intravenously to 16 end-stage colorectal cancer patients to assess safety, immunological reactions and tumor response. Immune responses were also evaluated and both p53-specific humoral and cellular responses were observed. 24 The patient who showed stable disease after additional compassionate use-vaccinations with the full dose, illustrates that immune reactions may take time to develop and may need boosting to achieve clinical effects. Importantly, the antitumor effect occurred in the absence of damage to healthy cells and the vaccine-related toxicity was minimal, even after repetitive administrations. Fever was the only adverse event that was consistently related to ALVAC-p53 treatment and was most outspoken in patients who received the highest dose of ALVAC-p53. However, there was evidence in one patient, that vaccine-induced fever could be prevented with the use of nonsteroidal anti-inflammatory drugs.
Other adverse events consisted mainly of tumorrelated complications, such as abdominal pain, fatigue, elevated liver enzymes and anemia. These symptoms occur frequently in end-stage colorectal cancer patients. [25] [26] [27] Mutations in the p53 gene occur in approximately 50% of malignancies and usually result in overexpression in the malignant cells only. 3 The combination of increased steady-state levels and predominant expression by malignant cells provided an opportunity for a p53-specific immunotherapeutic intervention. Experimental animal models have shown that the induction of anti-p53 responses can be used to eradicate p53-overexpressing tumors without toxicity or autoimmunity. 28, 29 The safety of the ALVAC canarypox virus as a vector as well as its ability to induce an immune response against the product of the incorporated gene has been well established in various malignancies 30, 31 and infectious diseases. 15, [32] [33] [34] Other viral vectors may be less efficient owing to preexisting anti-viral antibodies, 35 the immunogenicity of the viral vector or toxicity. 36, 37 For instance, a study in which adenovirus encoding wild-type p53 was injected intratumorally in patients with advanced non-small cell lung cancer did not result in the induction of an anti-p53 response. 35 Despite the significant immune suppression in the endstage cancer patients participating in our trial, immune responses against p53 were induced in the group that received the highest ALVAC-p53 dose. 24 This positive immune response was not accompanied by significant clinical responses, but this was not surprising in view of the fact that these patients had large tumor burdens that were diagnosed 25 months on average before treatment with ALVAC-p53. As we evaluated the tumor response a long time (14 weeks) after completing vaccinations, it is possible that ALVAC-p53 did induce a clinical response, but that this response was no longer detectable 14 weeks later. Other investigators report anti-tumor responses in end-stage patients, but assess these earlier after stopping the experimental treatment, for example, from 0 weeks, 25 2 weeks, 4 weeks, 26 4-6 weeks, 38 or 8 weeks 39 after stopping treatment. However, we observed disease progression at occasional earlier radiographic evaluations, such as in patients 02 (1/10 dose), 09 (1/3 dose) and 17 (full dose) who underwent CT scans on week 2, 4 weeks and 8 weeks after the last vaccination, respectively. Most interestingly, we documented stable disease 7 weeks after the completion of a second cycle of treatment with the full dose in a patient who had had a first cycle of treatment with 1/3 dose previously. The observed increase in IgG antibody titer against p53 after the vaccination cycles may indeed reflect the slow induction of an immune response induced by the vaccinations. Alternatively, it may reflect an increase in tumor burden. 40, 41 Although this was observed in only one subject, this indicates that it might be necessary to repeat vaccinations more often, as suggested by others, 42 while using NSAIDs to prevent the postvaccination fever.
The safety profile described here and the ability to induce anti-p53 responses have prompted us to further optimize the ALVAC-p53 vaccine, for instance by using multiple tumor antigens (e.g. CEA, Ep-Cam), adding costimulatory signals, and most importantly, by applying this strategy to patients who might truly benefit from this immune-mediated anti-cancer approach, that is, patients with minimal residual disease.
